Polyvalent human immunoglobulin for infectious diseases: Potential to circumvent antimicrobial resistance

Front Immunol. 2023 Jan 9:13:987231. doi: 10.3389/fimmu.2022.987231. eCollection 2022.

Abstract

Antimicrobial resistance (AMR) is a global health problem that causes more than 1.27 million deaths annually; therefore, it is urgent to focus efforts on solving or reducing this problem. The major causes of AMR are the misuse of antibiotics and antimicrobials in agriculture, veterinary medicine, and human medicine, which favors the selection of drug-resistant microbes. One of the strategies proposed to overcome the problem of AMR is to use polyvalent human immunoglobulin or IVIG. The main advantage of this classic form of passive immunization is its capacity to enhance natural immunity mechanisms to eliminate bacteria, viruses, or fungi safely and physiologically. Experimental data suggest that, for some infections, local administration of IVIG may produce better results with a lower dose than intravenous application. This review presents evidence supporting the use of polyvalent human immunoglobulin in AMR, and the potential and challenges associated with its proposed usage.

Keywords: antibiotic stewardship; antimicrobial resistance; human immunoglobulin; infection control; infectious diseases; misuse of antibiotics; public health.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Infective Agents* / pharmacology
  • Anti-Infective Agents* / therapeutic use
  • Communicable Diseases* / drug therapy
  • Drug Resistance, Bacterial
  • Humans
  • Immunoglobulins, Intravenous / pharmacology
  • Immunoglobulins, Intravenous / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Immunoglobulins, Intravenous
  • Anti-Infective Agents

Grants and funding

This work was supported by the normal budget from the Unit of Biochemistry at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, INCMNSZ and the Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, INER.